TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 410176

Group type: EXPERIMENTAL
Intervention: nitrangin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ergocomb
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: euphyllin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rocornal
Number of subjects: 31

Group type: COMPARATOR
Intervention: no additional therapy
Number of subjects: 31
Study: 30776911

Group type: EXPERIMENTAL
Intervention: Ancillary service needs (met and unmet)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Psychiatric health and substance use issues (depression, anxiety, drug use)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Reporting a specific individual need (met or unmet)
Number of subjects: 348
Study: 28668399

Group type: EXPERIMENTAL
Intervention: High intensity statin therapy (atorvastatin 80mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Moderate intensity statin therapy (atorvastatin 20mg/day)
Number of subjects: 130
Study: 25375664

Group type: EXPERIMENTAL
Intervention: Presence of patent foramen ovale (PFO)
Number of subjects: 57
Study: 23480523

Group type: EXPERIMENTAL
Intervention: Nurse-led ART
Number of subjects: 11882

Group type: COMPARATOR
Intervention: Doctor-led ART
Number of subjects: 11882
Study: 21665007

Group type: EXPERIMENTAL
Intervention: 50 mg of sertraline plus 2 g/day omega‐3 fatty acids
Number of subjects: 122

Group type: COMPARATOR
Intervention: 50 mg of sertraline plus 2 g/day corn oil placebo capsules
Number of subjects: 122
Study: 19426182

Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test: T)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate barrier (control: C)
Number of subjects: 15
Study: 16717207

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 15707254

Group type: EXPERIMENTAL
Intervention: Relaxation Techniques (RT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Music Comparison Condition
Number of subjects: 36
Study: 9159313

Group type: EXPERIMENTAL
Intervention: Povidone-iodine ointment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120
Study: 8422085

Group type: EXPERIMENTAL
Intervention: l-deprenyl (5 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 3655855

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CAFVP with MER)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Chemotherapy alone (CMF, CAF, CAFVP)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Chemotherapy (overall)
Number of subjects: 395
Study: 31987106

Group type: EXPERIMENTAL
Intervention: Rutin with vitamin C (group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vitamin C alone (group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Antidiabetic treatment only (group C)
Number of subjects: 53
Study: 29430796

Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study: 27102821

Group type: EXPERIMENTAL
Intervention: Soluble RSV fusion protein (sF) with 2.5μg glucopyranosyl lipid A (GLA) adjuvant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Soluble RSV fusion protein (sF) without adjuvant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Soluble RSV fusion protein (sF) with GLA adjuvant at highest dosage level
Number of subjects: 24
Study: 24441153

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 44
Study: 21424341

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 540
Study: 20735858

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus Saccharomyces boulardii
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral rehydration therapy plus placebo
Number of subjects: 64
Study: 18474338

Group type: EXPERIMENTAL
Intervention: Nesiritide (2 mug/kg bolus; 0.01 mug/kg/min for 48 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard therapy without nesiritide
Number of subjects: 72
Study: 15957695

Group type: EXPERIMENTAL
Intervention: Remifentanil (RG; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (CG; n=20)
Number of subjects: 40
Study: 12401625

Group type: EXPERIMENTAL
Intervention: Postoperative 0.5% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative 2% lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both preoperative 2% lidocaine and postoperative 0.5% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study: 10457394

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) filtration daily over five days (group A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Riluzole treatment only (group B)
Number of subjects: 10
Study: 7573786

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 666

Group type: COMPARATOR
Intervention: Malnutrition
Number of subjects: 666
Study: 2104077

Group type: EXPERIMENTAL
Intervention: 2 g sucralfate daily at bedtime
Number of subjects: 77

Group type: COMPARATOR
Intervention: 1 g sucralfate four times daily (q.d.s.)
Number of subjects: 77
Study: 350500

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 40
Study: 30964971

Group type: EXPERIMENTAL
Intervention: Philips Sonicare powered toothbrush (PTB)
Number of subjects: 148

Group type: COMPARATOR
Intervention: American Dental Association (ADA) reference manual toothbrush (MTB)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: PTB
Number of subjects: 148

Group type: COMPARATOR
Intervention: MTB
Number of subjects: 148
Study: 27926975

Group type: EXPERIMENTAL
Intervention: LGA
Number of subjects: 50734

Group type: COMPARATOR
Intervention: AGA
Number of subjects: 50734
Study: 26040334

Group type: EXPERIMENTAL
Intervention: Radial access route
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Femoral access route
Number of subjects: 1857
Study: 23566568

Group type: EXPERIMENTAL
Intervention: Medial retinaculum plasty (MRP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both MRP and MPFLR
Number of subjects: 70
Study: 21616771

Group type: EXPERIMENTAL
Intervention: High carbohydrate (H-CHO; 60% of daily caloric intake)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low carbohydrate (L-CHO; 30% of daily caloric intake)
Number of subjects: 16
Study: 19768691

Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16968916

Group type: EXPERIMENTAL
Intervention: Malarone (250 mg atovaquone plus 100 mg proguanil hydrochloride) daily from 1 day before entering the endemic area to 7 days after leaving the endemic area
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Malarone
Number of subjects: 180
Study: 15226514

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Infliximab treatment continued for 2 years
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Infliximab infusions every 8 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Long-term model for infliximab treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 70
Study: 11743484

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate and 61% ethyl alcohol (CHG/ethanol)
Number of subjects: 137

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate (CHG)
Number of subjects: 137

Group type: COMPARATOR
Intervention: 61% ethyl alcohol (control)
Number of subjects: 137
Study: 11195315

Group type: EXPERIMENTAL
Intervention: Spinal OA in females
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal OA in males
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bone resorption markers in OA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bone formation markers in OA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-OA)
Number of subjects: 60
Study: 9064269

Group type: EXPERIMENTAL
Intervention: thiamine/pyridoxine
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: benfotiamine/pyridoxine
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: nucleotides of cytidine and uridine
Number of subjects: 303

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 303
Study: 1478796

Group type: EXPERIMENTAL
Intervention: Acetyl-carnitine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 6719982

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of acebutolol and nifedipine
Number of subjects: 0
Study: 28861729

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm, 2 W, pulse interval 200 μs; pulse length 100 μs, 400-μm initiated fiber tip)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Scalpel (control)
Number of subjects: 18
Study: 26045552

Group type: EXPERIMENTAL
Intervention: Myrtus communis L. freeze-dried aqueous extract (1000 mg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omeprazol (20 mg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of Myrtus communis and Omeprazol
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 45
Study: 25457739

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 434

Group type: COMPARATOR
Intervention: Behavioral therapies
Number of subjects: 434
Study: 22481696

Group type: EXPERIMENTAL
Intervention: Flutter VRP1®
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ELTGOL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 20103724

Group type: COMPARATOR
Intervention: Topical perillyl alcohol (POH) cream, low dose (0.76% w/w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical perillyl alcohol (POH) cream, high dose
Number of subjects: 0
Study: 18054632

Group type: EXPERIMENTAL
Intervention: 25-gauge transconjunctival sutureless vitrectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: 20-gauge standard vitrectomy
Number of subjects: 57
Study: 16140708

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day for 4 weeks, followed by lovastatin 40 mg/day for 20 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diet plus placebo
Number of subjects: 54
Study: 11849912

Group type: EXPERIMENTAL
Intervention: Dissolution under fed conditions with dietary components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dissolution under fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro modeling of in vivo conditions
Number of subjects: 0
Study: 11783228

Group type: EXPERIMENTAL
Intervention: Shenlian Ear-Drops (SLED), three times per day
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ofloxacin ear-drop, three times per day
Number of subjects: 201
Study: 7723442

Group type: EXPERIMENTAL
Intervention: Multicenter AIDS Clinical Group Trials (n = 1,907)
Number of subjects: 2112

Group type: COMPARATOR
Intervention: Nontrial sample (n = 205)
Number of subjects: 2112
Study: 2190900

Group type: EXPERIMENTAL
Intervention: Pyroglutamic acid (PCA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30990099

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring containing ethinylestradiol 3.47 mg and etonogestrel 11.00 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Contraceptive vaginal ring containing ethinylestradiol 2.7 mg and etonogestrel 11.7 mg
Number of subjects: 58
Study: 29649978

Group type: EXPERIMENTAL
Intervention: Personalized objects (e.g., cigarette, paper)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-personalized objects
Number of subjects: 21
Study: 27444570

Group type: EXPERIMENTAL
Intervention: Trace conditioning paradigm using neutral tones as CS+ and alerting sounds as UCS
Number of subjects: 29
Study: 24268886

Group type: EXPERIMENTAL
Intervention: AUDIT administered at baseline with a cut-point of 8 or above
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: AUDIT administered at baseline
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: High expectations to drink post-release
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: Past amphetamine-type stimulant (ATS) use
Number of subjects: 1325
Study: 22433034

Group type: EXPERIMENTAL
Intervention: Alloy Primer (AP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Z‐Primer Plus (ZP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH + Alloy Primer (NaOH-AP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH + Z‐Primer Plus (NaOH-ZP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group) (CR)
Number of subjects: 60
Study: 20708496

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (20 min of daily exercise in the classroom)
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4700
Study: 18570266

Group type: EXPERIMENTAL
Intervention: 150 mg Pycnogenol per day at meals
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15852988

Group type: EXPERIMENTAL
Intervention: 0.8% halothane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane
Number of subjects: 75
Study: 12704070

Group type: EXPERIMENTAL
Intervention: BCNU polymer wafers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control wafers
Number of subjects: 20
Study: 10074011

Group type: EXPERIMENTAL
Intervention: Iron supplemented formula milk
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unmodified cows' milk
Number of subjects: 100
Study: 8933551

Group type: EXPERIMENTAL
Intervention: 4 x 10(6) pfu RRV‐TV
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 4 x 10(6) pfu RRV‐TV (older infants)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV (older infants)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV (younger infants)
Number of subjects: 195
Study: 1906830

Group type: EXPERIMENTAL
Intervention: 0.03 mg estriol vaginal tablets
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 15
Study: 6227756

Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim at night
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1,000 mg methenamine hippurate every 12 hours
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine solution, cleansing twice daily
Number of subjects: 64
Study: 30712751

Group type: EXPERIMENTAL
Intervention: Yoga intervention (60 minutes per session, three sessions per week for two months)
Number of subjects: 62
Study: 28225475

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (sedentary lifestyle)
Number of subjects: 50
Study: 25684277

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 0
Study: 24365961

Group type: EXPERIMENTAL
Intervention: BeZuHG (early discharge followed by home treatment service)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU (regular inpatient stay)
Number of subjects: 100
Study: 22930458

Group type: EXPERIMENTAL
Intervention: Left atrial surgical ablation (group A)
Number of subjects: 224

Group type: COMPARATOR
Intervention: No ablation (group B)
Number of subjects: 224
Study: 19476473

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Metformin (titrated to 1500 mg daily)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 335

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 335
Study: 17502494

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (3.3 to 55 pmol/min per 1000 mL forearm volume)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (55 pmol/1000 mL per min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral fludrocortisone (0.3 mg/d for 2 weeks)
Number of subjects: 18
Study: 15343450

Group type: EXPERIMENTAL
Intervention: Corneal transplant after penetrating eye injury (study group S)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Corneal transplant in patients with Fuchs' endothelial dystrophy (control group K)
Number of subjects: 44
Study: 11641371

Group type: EXPERIMENTAL
Intervention: Oral ribose supplementation (4 doses/day at 4 g/dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9734766

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incremental bolus of propofol
Number of subjects: 0
Study: 7989402

Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup 70 mg/ml administered 20-40 min prior to procedure
Number of subjects: 596
Study: 2643443

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 29173214

Group type: EXPERIMENTAL
Intervention: Text warnings
Number of subjects: 215

Group type: COMPARATOR
Intervention: Ultra-processed food images
Number of subjects: 215
Study: 26823240

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (HnBB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 25640116

Group type: EXPERIMENTAL
Intervention: Human breast milk (HBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment
Number of subjects: 0
Study: 24006749

Group type: EXPERIMENTAL
Intervention: Laminaria jam enriched with chromium (20 g daily containing 280 microg of iodine and 66 microg of chromium)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laminaria jam enriched with chromium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (comparison group)
Number of subjects: 50
Study: 21106985

Group type: EXPERIMENTAL
Intervention: Autografting (n = 112)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Observation (n = 111)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 223
Study: 18356327

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-containing dark chocolate bar with added sterol esters (1.1 g sterol esters per bar)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-containing dark chocolate bar
Number of subjects: 49
Study: 16214598

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg to 45 mg)
Number of subjects: 5238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238
Study: 12352276

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10408591

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 34

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination with diuretic (hydrochlorothiazide)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both ACE inhibitors
Number of subjects: 34
Study: 7580638

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Current users of tamoxifen
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Non-users of tamoxifen
Number of subjects: 1312
Study: 1979188

Group type: EXPERIMENTAL
Intervention: Plasmapheresis followed by reinfusion of unfrozen autologous plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medicamentous treatment alone (control group)
Number of subjects: 0
Study: 7015540

Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30586698

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) pump
Number of subjects: 361

Group type: COMPARATOR
Intervention: HeartMate II (HMII) pump
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Stroke events (any type)
Number of subjects: 361
Study: 28056024

Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole (for STH-positive mothers)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Placebo (for STH-positive mothers)
Number of subjects: 1010
Study: 25900659

Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 23373620

Group type: EXPERIMENTAL
Intervention: 200 mg aspirin for 30 days and 180 mg ticagrelor for 1 year
Number of subjects: 632

Group type: COMPARATOR
Intervention: Standard antiplatelet regimen
Number of subjects: 632
Study: 21294929

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xylose (50 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8